Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04203316
Title Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Children's Oncology Group

acute myeloid leukemia



Age Groups: adult | child
Covered Countries USA | CAN

Additional content available in CKB BOOST